The KLEAN study of fosamprenavir-ritonavir versus lopinavir-ritonavir, each in combination with abacavir-lamivudine, for initial treatment of HIV infection over 48 weeks: a randomised non-inferiority trial

This publication has 12 references indexed in Scilit:

• Baseline HIV‐1 RNA Level and CD4 Cell Count Predict Time to Loss of Virologic Response to Nelfinavir, but Not Lopinavir/Ritonavir, in Antiretroviral Therapy–Naive Patients
  The Journal of Infectious Diseases, 2004
• Treatment for Adult HIV Infection
  JAMA, 2004
• Efficacy and Safety of Tenofovir DF vs Stavudine in Combination Therapy in Antiretroviral-Naive PatientsA 3-Year Randomized Trial
  JAMA, 2004
• SOLO
  AIDS, 2004
• Triple-Nucleoside Regimens versus Efavirenz-Containing Regimens for the Initial Treatment of HIV-1 Infection
  New England Journal of Medicine, 2004
• GW433908/ritonavir once daily in antiretroviral therapy-naive HIV-infected patients
  AIDS, 2004
• Incidence of Resistance in a Double‐Blind Study Comparing Lopinavir/Ritonavir Plus Stavudine and Lamivudine to Nelfinavir plus Stavudine and Lamivudine
  The Journal of Infectious Diseases, 2004
• Decline in the AIDS and death rates in the EuroSIDA study: an observational study
  The Lancet, 2003
• Antiretroviral Drug Resistance Testing in Adults Infected with Human Immunodeficiency Virus Type 1: 2003 Recommendations of an International AIDS Society–USA Panel
  Clinical Infectious Diseases, 2003
• Lopinavir–Ritonavir versus Nelfinavir for the Initial Treatment of HIV Infection
  New England Journal of Medicine, 2002